ArticleInternational journal of hematology2020

Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies.

Naoyuki Uchida et al.PubMed ↗Publisher ↗

No numbers read from the abstract.